Professor Steve Schey is a Professor of Haematology based at King's College Hospital in London.

Prof Schey qualified at St George's Hospital in 1974, and later travelled to Australia where he worked at the Institute of Clinical Pathology and Medical Research in Sydney as Clinical Lecturer in Haematology.

He returned to London where he was the Bone Marrow Transplant Co-ordinator at the Royal Free Hospital and then the Royal Marsden. Later he moved to the Middlesex Hospital and subsequently served as Director of Clinical Haematology for the Guy's/St Thomas' Trust from 1993-2004 before moving to King’s College Hospital in 2005.

Professor Steve Schey was Secretary and then Chair of the UK Myeloma Forum 1999-2009. He has been Clinical Lead for South East Thames Cancer Network, since 2005. In addition, he is amember of the National Cancer Research Institute (NCRI) Haemoncology Cancer Steering Group, the NCRI Industry Adoption Panel and Chairman of the NCRI Myeloma Clinical Trials Committee.

Professor Chris Nutting is a Professor of Clinical Oncology based at The Royal Marsden Hospital, London.

Prof Nutting is a world leading Oncologist.  Operating from his Central and West London practices, he specialises in the management of cancer of the head and head, thyroid, thorax and other forms. He is an expert in solid cancer treatment with state of the art radiotherapy techniques such as conformal and intensity modulated radiotherapy designed to reduce complications of treatment and improve cure rates.

In June 2001 Professor Nutting was appointed Consultant and Senior Lecturer in Clinical Oncology at the Royal Marsden Hospital, where his clinical responsibilities and special interests include the management of patients with head and neck and lung cancers. He is the Clinical Director of the Head and Neck Unit at the Royal Marsden Hospital in London.

He has an extensive clinical practice in head, neck and lung cancer and participates in Nation Research protocols. He is regularly asked to speak at National and International clinical meetings on head and neck and lung tumours.

Professor Robert Huddart is a Consultant Clinical Oncologist based at The Royal Marsden Hospital.

Prof Huddart joined The Royal Marsden as a Registrar in 1989 and was appointed Senior Lecturer and Honorary Consultant in Clinical Oncology at The Royal Marsden and The Institute of Cancer Research in 1995.

Prof Huddart is a Reader in Urological Oncology (since 2007) at the Institute of Cancer Research (ICR), leading a team in the Division of Radiotherapy and Imaging that researches bladder and testicular cancer. He is one of the ICR’s top scientists in the Everyman laboratories and also an Honorary Consultant in Urological Oncology at The Royal Marsden, where he manages and treats patients with urological cancer - cancer that affects the kidney, bladder, prostate, testicles and penis.

He completed a Master of Arts and a Bachelor of Medicine at Oxford, and a Bachelor of Surgery at the University of London before undertaking general medical training in Oxford and Cambridge. He gained membership to the Royal College of Physicians and then moved to The Royal Marsden for specialist training in oncology. Dr Huddart was awarded gold medals in both stages of the examination to become a Fellow of the Royal College of Radiologists. He first joined the ICR to complete a PhD in the molecular biology of testicular cancer with Professor Colin Cooper.

“Working as a clinical academic at the ICR and The Royal Marsden provides an almost unique opportunity in the UK of working and researching at the cutting edge of oncology, meeting and working with some of the UK's top cancer scientists and being able to investigate and use new technologies and developments. This, combined with the excellence of cancer care within The Royal Marsden, means there is no better place, in my view, for an oncologist to be,” says Prof Huddart.

He recently retired (after 6 years) as Chair of the National Cancer Research Institute (NCRI) testicular cancer group, and jointly leads the ICR’s postgraduate course in oncology. Most recently, he has qualified for a Postgraduate Certificate in Education from University College, London. In the future, Dr Huddart hopes to be involved in “developing new personalised treatments which make a real impact on the outlook of the patients we see each week”. He continues to contribute nationally through the Royal College of Radiologists (currently sitting on Specialist Training Board and quality assurance subcommittee) and regionally as a member of the London School of Oncology Board and Training Program director.

Prof Huddart is a member of the following national groups: NCRI Testis Cancer Group, including survivorship sub-group; NCRI Bladder Cancer group, including its localised and advanced sub-groups; CT Rad workstream 3; NCIN urology site-specific reference group; NICE clinical guideline development group for bladder cancer.